Prometheus Biosciences Profit Margin

Prometheus Biosciences (RXDX) currently reports a profit margin of -3732.99% as of March 2023. That compares with -1749.08% in the prior-year period — down 113.4% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Prometheus Biosciences's profit margin history and peer comparisons.

Prometheus Biosciences's profit margin decreased from -1749.08% to -3732.99% — a 113.4% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Prometheus Biosciences's profit margin of -3732.99% is lower than the Healthcare sector average of 13.89%. That is roughly 26969.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Prometheus Biosciences's current -3732.99% should be judged against Healthcare norms (sector average: 13.89%) and against RXDX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -3732.99%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Prometheus Biosciences, and consider following RXDX for alerts when major investors trade the stock.